SEC Form 4 · accession 0001209191-19-019399
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
G Bradley Cole
Officer — CFO
Period of report
Mar 12, 2019
Accepted (ET)
Mar 14, 2019 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 12, 2019 | M | 5,000 | $17.18 | A | 48,722 | I | Held by the Cole Family Trust |
| Common StockF1 | Mar 12, 2019 | M | 10,000 | $22.98 | A | 58,722 | I | Held by the Cole Family Trust |
| Common StockF2,F3,F4,F1 | Mar 12, 2019 | S | 4,000 | $74.984 | D | 54,722 | I | Held by the Cole Family Trust |
| Common StockF2,F3,F5,F1 | Mar 12, 2019 | S | 1,000 | $75.805 | D | 53,722 | I | Held by the Cole Family Trust |
| Common StockF6,F3,F7,F1 | Mar 12, 2019 | S | 7,900 | $74.9768 | D | 45,822 | I | Held by the Cole Family Trust |
| Common StockF6,F3,F8,F1 | Mar 12, 2019 | S | 2,100 | $75.8167 | D | 43,722 | I | Held by the Cole Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F9 | $17.18 | Mar 12, 2019 | M | 5,000 | D | — | Feb 18, 2020 | Common Stock | 5,000 | 21,471 | D |
| Employee Stock Option (right to buy)F10 | $22.98 | Mar 12, 2019 | M | 10,000 | D | — | Jan 27, 2021 | Common Stock | 10,000 | 16,424 | D |
Explanation of responses
- F1Includes an aggregate of 11,794 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F10The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 4, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $74.53 to $75.42.
- F5Represents weighted average sale price. Actual sale prices ranged from $75.64 to $75.96.
- F6These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 23, 2018.
- F7Represents weighted average sale price. Actual sale prices ranged from $74.52 to $75.44.
- F8Represents weighted average sale price. Actual sale prices ranged from $75.66 to $76.04.
- F9The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.